[Antibacterial therapy in surgery of patients with acute destructive appendicitis].
Character of microflora of exsudate of abdominals and mucosis microflora of vermicular appendix is studied for patients with the destructive forms of appendicitis with the purpose of development of variants of antibacterial therapy at surgical treatment of patients with acute appendicitis. The patients with the destructive forms of appendicitis, which were on treatment in a municipal clinical hospital N 4 Kyiv for period 2004-2010. An Inflammatory-destructive process in an appendix is conditioned by both aerobic (Escherichia coli - 46,6 %, Enterobacter - 4,2 %, Citrobacter - 4,2 %, Klebsiella - 3,3 %, Pseudomonas aeruginosa - 5,8 %, Staphylococcus - 4,2 %) and anaerobic microorganisms (Bacteroides - 100 %) and increase Candida - 17,5 %. Antibacterial therapy is effective at 46,7 % patients with acute appendicitis. At 49,6 % patients acute appendicitis develops on a background dysbiotic intestinal disturbances. Clinically the effective charts of empiric antibacterial monotherapy 6 days it is been: Moxifloxacini intravenously 400 mgs one time in twenty-four hours during, Ertapenemi for a 1 g one time in twenty-four hours intravenously and combined - Aztreonami for a 1 g twice in twenty-four hours and of Clindamycini for 600 mgs twice in twenty-four hours, intramuscular during; Cefepimumi for a 1 g twice in twenty-four hours and of Clindamycini for 600 mgs twice in twenty-four hours, intramuscular.
B H
BH
Bezrodnyĭ
I V
IV
Kolosovych
A V
AV
Iovitsa
L D
LD
Martynovych
R A
RA
Sydorenko
O M
OM
Sysak
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D001062:Appendectomy; D001064:Appendicitis / Q000188:drug therapy* / Q000382:microbiology / Q000601:surgery; D001065:Appendix / Q000187:drug effects / Q000382:microbiology / Q000601:surgery*; D001372:Aza Compounds / Q000008:administration & dosage; D001398:Aztreonam / Q000008:administration & dosage; D001420:Bacteria, Aerobic / Q000187:drug effects / Q000502:physiology; D001421:Bacteria, Anaerobic / Q000187:drug effects / Q000502:physiology; D002175:Candida / Q000187:drug effects / Q000502:physiology; D000077723:Cefepime; D002511:Cephalosporins / Q000008:administration & dosage; D002981:Clindamycin / Q000008:administration & dosage; D019468:Disease Management; D004333:Drug Administration Routes; D004334:Drug Administration Schedule; D000077727:Ertapenem; D005260:Female; D024841:Fluoroquinolones; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077266:Moxifloxacin; D011804:Quinolines / Q000008:administration & dosage; D047090:beta-Lactams / Q000008:administration & dosage
D000900:Anti-Bacterial Agents; D001372:Aza Compounds; D002511:Cephalosporins; D024841:Fluoroquinolones; D011804:Quinolines; D047090:beta-Lactams; D002981:Clindamycin; D000077723:Cefepime; D001398:Aztreonam; D000077727:Ertapenem; D000077266:Moxifloxacin